Hydroxyflutamide intraprostatic - LIDDS

Drug Profile

Hydroxyflutamide intraprostatic - LIDDS

Alternative Names: Liproca Depot

Latest Information Update: 23 Mar 2016

Price : $50

At a glance

  • Originator LIDDS
  • Developer LIDDS; Uppsala University
  • Class Anilides; Antiandrogens; Antineoplastics; Small molecules
  • Mechanism of Action Testosterone congener inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Prostate cancer

Most Recent Events

  • 30 Jul 2015 Phase-II development is ongoing in Finland and Sweden
  • 21 Jun 2011 Phase-II clinical trials in Prostate cancer in Sweden (Intraprostatic)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top